4.7 Letter

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Related references

Note: Only part of the references are listed.
Article Oncology

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Carlo Gambacorti-Passerini et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)

Article Medicine, General & Internal

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, General & Internal

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)